CoChat

CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling

Open access
Choi, Hee‐Joo, Jin, Sora, Cho, Hani, Won, Hee‐Young, An, Hee Woon, Jeong, Ga‐Young, Park, Young‐Un, Kim, Hyung‐Yong, Park, Mi Kyung, Son, Taekwon, Min, Kyueng‐Whan, Jang, Ki‐Seok, Oh, Young‐Ha, Lee, Jeong‐Yeon, Kong, Gu · 2019 · EMBO reports
Cited by 117

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Cyclin‐dependent kinase 12 (CDK12) has emerged as an effective therapeutic target due to its ability to regulate DNA damage repair in human cancers, but little is known about the role of CDK12 in driving tumorigenesis. Here, we demonstrate that CDK12 promotes tumor initiation as a novel regulator of cancer stem cells (CSCs) and induces anti‐HER2 therapy resistance in human breast cancer. High CDK12 expression caused by concurrent amplification of CDK12 and HER2 in breast cancer patients is associated with disease recurrence and poor survival. CDK12 induces self‐renewal of breast CSCs and in vivo tumor‐initiating ability, and also reduces susceptibility to trastuzumab. Furthermore, CDK12 kinase activity inhibition facilitates anticancer efficacy of trastuzumab in HER2+ tumors, and mice bearing trastuzumab‐resistant HER2+ tumor show sensitivity to an inhibitor of CDK12. Mechanistically, the catalytic activity of CDK12 is required for the expression of genes involved in the activation of ErbB‐PI3K‐AKT or WNT‐signaling cascades. These results suggest that CDK12 is a major oncogenic driver and an actionable target for HER2+ breast cancer to replace or augment current anti‐HER2 therapies. CDK12, a RNA polymerase II kinase, promotes breast cancer stem cell‐like properties mediated by WNT and ErbB‐PI3K signaling. Targeting CDK12 improves trastuzumab therapy in breast cancers characterised by HER2/CDK12 co‐amplification. CDK12 amplification induces tumor initiation and progression, and mediates trastuzumab resistance. CDK12 is required for transcriptional upregulation of genes involved in ErbB‐PI3K and WNT pathway activation. CDK12 inhibition alone or in combination with trastuzumab therapy has anti‐tumor activity against HER2+ breast cancers. CDK12 amplification induces tumor initiation and progression, and mediates trastuzumab resistance. CDK12 is required for transcriptional upregulation of genes involved in ErbB‐PI3K and WNT pathway activation. CDK12 inhibition alone or in combination with trastuzumab therapy has anti‐tumor activity against HER2+ breast cancers. CDK12, a RNA polymerase II kinase, promotes breast cancer stem cell‐like properties mediated by WNT and ErbB‐PI3K signaling. Targeting CDK12 improves trastuzumab therapy in breast cancers characterised by HER2/CDK12 co‐amplification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/embr.201948058

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 117

Metadata

Authors
Choi, H., Jin, S., Cho, H., Won, H., An, H. W., Jeong, G., Park, Y., Kim, H., Park, M. K., Son, T., Min, K., Jang, K., Oh, Y., Lee, J., & Kong, G.
Venue
EMBO reports
Published
2019-08-30
Volume
20
Issue
10
Pages
e48058-e48058
ISSN
  • 1469-221X (ISSN-L)
  • 1469-3178
OpenAlex
W2971050114
Cited by
117
References
13
FWCI
4.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling. https://app.cochat.ai/papers/10.15252/embr.201948058
The paper
Choi, H., Jin, S., Cho, H., Won, H., An, H. W., Jeong, G., Park, Y., Kim, H., Park, M. K., Son, T., Min, K., Jang, K., Oh, Y., Lee, J., & Kong, G. (2019). CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling. EMBO reports. https://doi.org/10.15252/embr.201948058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.